All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
BCMA is a suitable candidate for CAR-T therapies because it is absent on hematopoietic stem cells but selectively expressed on PCs, and BCMA is almost present in MM cells. Proliferation-inducing ligand (APRIL) is a natural ligand for both BCMA.
Creative Biolabs provides a second-generation CAR vector which is designed using IL-11 peptide/protein as the extracellular domain. The vector is constructed for the engineering of T cells to target Human IL-20Rα.
There are currently no customer reviews or questions for APRIL (BCMA Receptor) h(CD28-CD3ζ) Ligand-based CAR, pCDCAR1 (XS-1222-ZP13). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION